Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Pages: 65 Published: June 30, 2022 Report Code: GDHC072CL

Waldenstrom macroglobulinemia (WM) is a rare blood cell cancer characterized by the production of large amounts of an abnormal protein (called macroglobulin) by cancer cells. WM is a type of non-Hodgkin lymphoma (NHL) and is also known as lymphoplasmacytic lymphoma. WM is a low-grade B cell lymphoproliferative neoplasm characterized by small lymphocytes and monoclonal immunoglobulin M (IgM) monoclonal gammopathy. WM cells have features of both plasma cells and lymphocytes and are called lymphoplasmacytoid.

The Waldenstrom Macroglobulinemia marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for Waldenstrom Macroglobulinemia. Moreover, it analyzes the clinical and commercial landscapes of Waldenstrom Macroglobulinemia, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Waldenstrom Macroglobulinemia Marketed and Pipeline Drugs Overview by Mechanism of Action

The major mechanisms of action in the Waldenstrom Macroglobulinemia marketed and pipeline drugs market are enzyme inhibitor, receptor agonist, genes, nucleic acids & related components inhibitor, protein & peptide inhibitor, cytotoxic to cell, receptor inhibitor, receptor antagonist, protein & peptide activator, antigen inhibitor, biological factor activator, and biological factor inhibitor.

Waldenstrom Macroglobulinemia Marketed and Pipeline Drugs Market Analysis by Mechanism of Action

Waldenstrom Macroglobulinemia Marketed and Pipeline Drugs Market Analysis by Mechanism of Action

For more mechanism of action insights, download a free report sample

Waldenstrom Macroglobulinemia Marketed and Pipeline Drugs Overview by Routes of Administration

The major routes of administration in the Waldenstrom Macroglobulinemia marketed and pipeline drugs market are oral therapies, suppository therapies, injections, topical therapies, and inhalational therapies.

Waldenstrom Macroglobulinemia Marketed and Pipeline Drugs Market Analysis by Routes of Administration

Waldenstrom Macroglobulinemia Marketed and Pipeline Drugs Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Market Report Overview

Major Mechanism of Action Enzyme Inhibitor, Receptor Agonist, Genes, Nucleic Acids & Related Components Inhibitor, Protein & Peptide Inhibitor, Cytotoxic to Cell, Receptor Inhibitor, Receptor Antagonist, Protein & Peptide Activator, Antigen Inhibitor, Biological Factor Activator, and Biological Factor Inhibitor
Major Routes of Administration Oral Therapies, Suppository Therapies, Injections, Topical Therapies, and Inhalational Therapies

Scope

GlobalData’s Waldenstrom Macroglobulinemia: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, and Route of Administration
  • Product Profiles with Sales Forecast
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Waldenstrom Macroglobulinemia market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Waldenstrom Macroglobulinemia market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Route of Administration

4.4 Overview by Molecule Type

4.5 Marketed Drugs Profiles and Sales Forecasts

5 Pipeline Drugs Assessment

5.1 Late-stage Pipeline Drugs

5.2 Overview by Development Stage

5.3 Overview by Mechanism of Action

5.4 Overview by Route of Administration

5.5 Overview by Molecule Type

5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

5.7 Therapy Area and Indication-specific PTSR and LoA

6 Clinical Trials Assessment

6.1 Historical Overview

6.2 Overview by Phase

6.3 Overview by Status

6.4 Overview by Phase for Ongoing and Planned Trials

6.5 Trials with Virtual Components

6.6 Geographic Overview

6.7 Single-Country and Multinational Trials by Region

6.8 Top 20 Sponsors with Breakdown by Phase

6.9 Top 20 Sponsors with Breakdown by Status

6.10 Overview by Endpoint Status

6.11 Overview by Race and Ethnicity

6.12 Enrollment Data

6.13 Top 20 countries for Trial Sites

6.14 Top 20 Sites Globally

6.15 Feasibility Analysis – Geographic Overview

6.16 Feasibility Analysis – Benchmark Models

7 Deals Landscape

7.1 Mergers, Acquisitions, and Strategic Alliances by Region

7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

10.1 Methodology

10.2 Methodology – PTSR and LoA Analysis

10.3 About the Authors

10.4 Contact Us

10.5 Disclaimer

Frequently Asked Questions

Request a Free Sample
$3495

Can be used by individual purchaser only

$10485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.